gsie

[gsie]

Legislators looked puzzled. Had they entered an Agatha Christie novel? The detective arched an eyebrow. “How can you be so sure?”

[gsie]

Microsoft is working on a native Arm64 version of Visual Studio 2022 and a miniature Arm PC. A preview version of an Arm native version of Visual Studio 2022 will be available “in the next few weeks” and is expected to ship fully later this year alongside Arm64 .NET support.

[gsie]

On­ly about half of a se­lect group of clin­i­cal tri­als could be well-em­u­lat­ed with avail­able re­al world ev­i­dence, ac­cord­ing to the new­ly dis­cussed re­sults of an FDA pi­lot pro­gram.

[gsie]

The way biotech veteran Alexis Borisy and entrepreneur Zach Weinberg see it, the venture capital model is unfair. Or at the very least, a little one-sided. Scores of scientific founders work inside incubators at top biotech VC firms, creating companies specifically for them.

[gsie]

And why this professor thinks we need a revolution. Do you have a job that you secretly believe is pointless?

[gsie]

This is a carousel. Use Next and Previous buttons to navigate Opening Friday in downtown Winters (Yolo County), the tasting room will offer flights ($10-$17) of the six L’Apero les Trois aperitifs paired with French-inspired small plates.

[gsie]

This is a natural wine bar for everyone, the sort of place where Zoomers could bring their parents and all would feel at home. Earlier in the evenings, before the dancing kick in, it can feel like a restaurant, with diners enjoying a relatively quiet steak dinner.

[gsie]

A privacy-first, open-source platform for knowledge management and collaboration.

[gsie]

If you buy something from a Verge link, Vox Media may earn a commission. See our ethics statement. Thirty five hundred lumens is a lot of output from an ultra-short throw (UST) all-in-one 4K projector.

[gsie]

Catalio Capital Management has seen a flurry of deal activity across its 45 portfolio companies in its nascent history, and the investor is ready to bankroll the next slate of drug developers, device makers, diagnostics creators and data companies with its third fund.

[gsie]

The nights are the hardest, when he lies there on his cot, the whine of the air-raid sirens in his ears and his phone still buzzing beside him. Its screen makes his face look like a ghost in the dark, his eyes scanning messages he didn’t have a chance to read during the day.

[gsie]

Tran­si­tion­ing a de­vel­op­ing com­pound from ear­ly phase clin­i­cal tri­als to a piv­otal tri­al(s) can be a make-or-break de­ci­sion for a small- or medi­um-sized phar­ma. And some­times com­pa­nies aren’t very good at mak­ing the right de­ci­sion.

[gsie]

The first and newest de­vel­op­ment is the fi­nanc­ing, as Oc­tant — head­ed up by for­mer UCLA pro­fes­sor Sri Ko­suri and found­ed in 2017 — raised $80 mil­lion in a Se­ries B round.

[gsie]

Throughout the history of medicine, drug developers have tried to make clinical trials faster and more efficient.

[gsie]

As drug de­vel­op­ers and reg­u­la­tors alike in­creas­ing­ly warm to cre­ative ideas for run­ning clin­i­cal tri­als, a ma­chine learn­ing plat­form cre­at­ed by three physi­cists is draw­ing in $50 mil­lion from tech VCs.